Affiliation: The Methodist Hospital
- A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphomaNianxi Zhao
Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
J Nanobiotechnology 9:2. 2011..However, siRNAs are not cell type-selective, cannot specifically target tumor cells, and therefore have limited in vivo application for siRNA-mediated gene therapy...
- Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivoJianguo Wen
Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin MS205, Houston, TX 77030, USA
Mol Cancer Ther 10:148-58. 2011..Our findings indicate that Cetrorelix induces cytotoxicity in myeloma cells through various mechanisms and provide a rationale for investigating Cetrorelix for the treatment of MM...
- Role of MAP kinases in anaplastic large cell lymphomaYouli Zu; Fiscal Year: 2007..More importantly, the resultant findings may lead to therapeutic advances for ALCL by identifying key signaling molecules in the lymphoma cells. ..
- A bifunctional nanomedicine for both specific imaging and targeting therapy of anYouli Zu; Fiscal Year: 2010..In addition, it should enable physicians to in vivo image ALCL tumors and monitor therapeutic responses in a real-time manner. ..